Endo's Qwo® (collagenase clostridium histolyticum-aaes) Data to Be Presented at The Aesthetic Meeting 2021

Rhea-AI Summary

Endo International plc (NASDAQ: ENDP) announced that data regarding Qwo^® (collagenase clostridium histolyticum-aaes), FDA-approved for treating cellulite in adult women, will be showcased at The Aesthetic Meeting 2021 in Miami from April 29 to May 3, 2021. Key presentations include studies on reduction in dimple volume and interim analysis of safety and effectiveness for thigh cellulite. Qwo is contraindicated for those with hypersensitivity to collagenase and has reported adverse reactions such as bruising in 84% of subjects.

Positive

• Presentation of Qwo data at a significant industry event.
• FDA approval highlights the market potential for Qwo.

Negative

• High incidence of injection site bruising (84%) reported in clinical trials.
• Contraindications limit the patient population eligible for treatment.

DUBLIN, April 29, 2021 /PRNewswire/ -- Endo International plc (NASDAQ: ENDP) announced today that data relevant to the use of Endo Aesthetics' Qwo^® (collagenase clostridium histolyticum-aaes), which received FDA approval in July 2020 for the treatment of moderate to severe cellulite in the buttocks of adult women, will be presented during The Aesthetic Meeting 2021.

This data will be highlighted in two oral presentations during the virtual and in-person meeting taking place in Miami, FL April 29–May 3, 2021.

• "Reduction in Dimple Volume in Women With Buttock Cellulite Treated With Collagenase Clostridium Histolyticum-aaes;" Lawrence Bass, M.D., medical director and founder, Bass Plastic Surgery, PLLC, and QWO clinical trial investigator; Sunday, May 2
• "Real-World Effectiveness and Safety of Collagenase Clostridium Histolyticum-aaes Injections for the Treatment of Thigh Cellulite in Women: An Interim Analysis;" Sachin Shridharani, M.D., F.A.C.S., founder, LUXURGERY^©, and QWO clinical trial investigator; Sunday, May 2

QWO will also be discussed during The Aesthetic Meeting's well-respected Premier Global Hot Topics program on Friday, April 30.

INDICATION
QWO is indicated for the treatment of moderate to severe cellulite in the buttocks of adult women.

IMPORTANT SAFETY INFORMATION FOR QWO

CONTRAINDICATIONS
QWO is contraindicated in patients with a history of hypersensitivity to collagenase or to any of the excipients or the presence of infection at the injection sites.

WARNINGS AND PRECAUTIONS
Hypersensitivity Reactions
Serious hypersensitivity reactions including anaphylaxis have been reported with the use of collagenase clostridium histolyticum. If such a reaction occurs, further injection of QWO should be discontinued and appropriate medical therapy immediately instituted. Advise patients to seek immediate medical attention if they experience any symptoms of serious hypersensitivity reactions.

Injection Site Bruising
In clinical trials, 84% of subjects treated with QWO experienced injection site bruising. Subjects with coagulation disorders or using anticoagulant or antiplatelet medications (except those taking ≤150 mg aspirin daily) were excluded from participating in Trials 1 and 2.

QWO should be used with caution in patients with bleeding abnormalities or who are currently being treated with antiplatelet (except those taking ≤150 mg aspirin daily) or anticoagulant therapy.

Substitution of Collagenase Products
QWO must not be substituted with other injectable collagenase products. QWO is not intended for the treatment of Peyronie's Disease or Dupuytren's Contracture.

ADVERSE REACTIONS
In clinical trials, the most commonly reported adverse reactions in patients treated with QWO incidence ≥ 10% were at the injection site: bruising, pain, nodule and pruritus.

Click for Full Prescribing Information for QWO.

About Cellulite
Cellulite is a localized alteration in the contour of the skin that has been reported in over 90 percent of post-pubertal females and affects women of all races and ethnicities.^1,2 The presence of cellulite is associated with changes in dermal thickness and in the fat cells and connective tissue below the skin.³ A primary factor in the cause of the condition is the collagen containing septae which attach the skin to the underlying fascia layers.^4,5 The septae tether the skin which, with additional contributing protrusions of subcutaneous fat, causes the surface dimpling characteristic of cellulite.^6,7 These fibrous septae are oriented differently with varying thickness in females than in males, which informs our understanding of cellulite as a gender-related condition.⁸ Cellulite clinically presents on the buttocks, thighs, lower abdomen and arms. 

It is known that cellulite is different from generalized obesity.⁹ In generalized obesity, adipocytes undergo hypertrophy and hyperplasia that is not limited to the pelvis, thighs, and abdomen.² In areas of cellulite, characteristic large, metabolically stable adipocytes have physiologic and biochemical properties that differ from adipose tissue located elsewhere.¹⁰ An anatomical study in 2019 found that women have increased fat lobule height compared with men, which may also contribute to the mattress-like appearance seen as a result of the tension of the fibrous septae.^8,10 Weight gain can make cellulite more noticeable, but cellulite may be present even in thin subjects.⁹

About Endo Aesthetics LLC
Endo Aesthetics is embarking on a mission devoted to pushing the boundaries of aesthetic artistry. Driven by world-class research and development, Endo Aesthetics is advancing solutions to address unmet needs beginning with the first FDA-approved injectable treatment for cellulite in the buttocks. Headquartered in Malvern, PA, Endo Aesthetics is an Endo International plc (NASDAQ: ENDP) business. Learn more at www.endoaesthetics.com.

About Endo
Endo (NASDAQ: ENDP) is a specialty pharmaceutical company committed to helping everyone we serve live their best life through the delivery of quality, life-enhancing therapies. Our decades of proven success come from a global team of passionate employees collaborating to bring the best treatments forward. Together, we boldly transform insights into treatments benefiting those who need them, when they need them. Learn more at www.endo.com or connect with us on LinkedIn.

Forward-Looking Statements
This press release contains certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and Canadian securities legislation, including, but not limited to, statements regarding research and development outcomes, safety, efficacy, effectiveness, adverse reactions, market and product potential and product availability. Statements including words such as "believes," "expects," "anticipates," "intends," "estimates," "plan," "will," "may," "look forward," "intend," "guidance," "future" or similar expressions are forward-looking statements. Because these statements reflect Endo's current views, expectations and beliefs concerning future events, they involve risks and uncertainties. Although Endo believes that these forward-looking statements and information are based upon reasonable assumptions and expectations, readers should not place undue reliance on them, or any other forward-looking statements or information in this news release. Investors should note that many factors, as more fully described in the documents filed by Endo with the Securities and Exchange Commission and with securities regulators in Canada on the System for Electronic Document Analysis and Retrieval, including under the caption "Risk Factors" in Endo's Form 10-K, Form 10-Q and Form 8-K filings, and as otherwise enumerated herein or therein, could affect Endo's future results and could cause Endo's actual results to differ materially from those expressed in forward-looking statements contained in this communication. The forward-looking statements in this press release are qualified by these risk factors. Endo assumes no obligation to publicly update any forward-looking statements, whether as a result of new information, future developments or otherwise, except as may be required under applicable securities laws.

References:

1. Hexsel DM, et al. Side-by-side comparison of areas with and without cellulite depressions using magnetic resonance imaging. Dermatol Surg. 2009;35(10):1471-7.
2. Khan MH, et al. Treatment of cellulite: Part I. Pathophysiology. J Am Acad Dermatol. 2010;62:361-70.
3. Querleux B, et al. Anatomy and physiology of subcutaneous adipose tissue by in vivo magnetic resonance imaging and spectroscopy: Relationships with sex and presence of cellulite. Skin Res Technol. 2002;8(2):118-24.
4. Zhang YZ, et al. Appl Environ Microbiol. 2015;81(18):6098-6107.
5. Rossi AM, Katz BE. Dermatol Clin. 2014;32(1):51-59.
6. Edkins TJ, et al. Clin Vaccine Immunol. 2012;19(4):562-569.
7. Kaplan FT. Drugs Today (Barc). 2011;47(9):653-667.
8. Rudolph C, et al. Structural gender-dimorphism and the biomechanics of the gluteal subcutaneous tissue – Implications for the pathophysiology of cellulite. Plast Reconstr Surg. 2019;143(4):1077-86.
9. Avram MM. Cellulite: a review of its physiology and treatment. J Cosmet Laser Ther. 2005;7:1-5.
10. Pierard GE, et al. Cellulite: from standing fat herniation to hypodermal stretch marks. Am J Dermatopathol. 2000;22(1):34-7.

 

View original content to download multimedia:http://www.prnewswire.com/news-releases/endos-qwo-collagenase-clostridium-histolyticum-aaes-data-to-be-presented-at-the-aesthetic-meeting-2021-301279739.html

SOURCE Endo International plc

FAQ

What new data is being presented for Qwo at The Aesthetic Meeting 2021?

Data regarding the efficacy and safety of Qwo will be presented, including the reduction in dimple volume and real-world effectiveness for thigh cellulite.

When is the Aesthetic Meeting 2021 where Endo will present Qwo data?

The Aesthetic Meeting 2021 takes place from April 29 to May 3, 2021, in Miami, FL.

What is Qwo indicated for according to the press release?

Qwo is indicated for the treatment of moderate to severe cellulite in the buttocks of adult women.

What are the common adverse reactions associated with Qwo?

Common adverse reactions include bruising, pain, nodules, and pruritus at the injection site, with bruising occurring in 84% of clinical trial subjects.

What contraindications are associated with Qwo?

Qwo is contraindicated in patients with a history of hypersensitivity to collagenase or any excipients and those with infections at injection sites.